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clinical trials, the guideline recommendations, the important aspects of patient selection and clinical practice,
new antidote drugs for NOACs and real-world data of NOACs in patients with non-valvular atrial ﬁbrillation
have been discussed.
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Atrial ﬁbrillation (AF) is the most common sustained cardiac ar-
rhythmia and is seen in 1–2% of the general population.1 The number
of patients with AF in the United States was 2.2 million in 2010 and is
expected to rise to 12 million by 2050.2 Ischaemic stroke and systemic
thromboembolism are the most severe and fatal complications of AF.
AF is responsible for 15% of the ischaemic stroke cases among all age
groups and this rate increases up to 30% in people older than
80 years.3 Warfarin is a vitamin K antagonist (VKA) that has been
used in the prevention of AF for over 50 years. Randomised trials have
shown that warfarin is superior to placebo, aspirin and the combination
of aspirin–clopidogrel in preventing stroke.4,5,6 Warfarin use is chal-
lenging due to its narrow therapeutic index and it has many food and
drug interactions. Thus, only 50 to 60% of the patients with AF are pre-
scribed warfarin therapy and in 30 to 50% of these patients the interna-
tional normalised ratio (INR) levels cannot be maintained within the
therapeutic index.7,8 Although the efﬁcacy of warfarin and other VKAs
has been proven, the low and suboptimal use has led to the develop-
ment of novel oral anticoagulants (NOACs).
Novel oral anticoagulants
Vitamin K antagonists affect the vitamin K dependent factors II,
VII, IX, and X of the coagulation cascade and novel oral anticoagulants
(NOACs) affect speciﬁc steps. They are classiﬁed according to their
effects as the direct thrombin inhibitors dabigatran and AZD0837,
and the direct factor Xa inhibitors rivaroxaban, apixaban, edoxaban,
betrixaban, LY-517,717 and ym-150 (Table 1).9 This review focuses
on dabigatran, rivaroxaban, apixaban and edoxaban that are approved
by the American Food and Drug Administration (FDA) for the preven-
tion of stroke and systemic embolism in patients with non-valvular
AF.
Dabigatran
Dabigatran etexilate is an oral pro-drug and is converted to its active
form dabigatran, a reversible, direct and competitive thrombin inhibitor
by serum esterases.10 Its half-life is 12–17 h, and 80% of the drug is ex-
creted renally.11 The RE-LY (Randomized Evaluation of Long-term
Anticoagulation TherapY) trial, is a prospective, randomised controlled
and open-labelled trial that compares the efﬁcacy and safety of
110 mg and 150 mg doses of dabigatran to warfarin with respect to
stroke and systemic embolisms. The trial was designed as a non-inferi-
ority trial. 18,113 patients withmean CHADS2 scores of 2.1 were includ-
ed in the trial and were randomised to receive dabigatran (110 mg or
150 mg, twice a day) or warfarin (INR 2–3). The primary endpoint
was stroke or systemic embolism.With respect to the primary endpoint,
the dose of 110 mg dabigatran (1.53% events/year) was non-inferior
(p b 0.001) to warfarin and the dose of 150 mg dabigatran
(1.1% events/year) was superior to warfarin (p b 0.001).12 The rate of
major and life-threatening bleeding in the group of 150 mg doses of
dabigatran was similar to warfarin (3.11% vs. 3.36% events/yearTable 1
Comparison of pharmacokinetic proﬁles for the novel oral anticoagulants.12,14,15,20
Dabigatran Rivaroxaban
Mechanism of action Direct thrombin (factor IIa) inhibition Direct factor X
Dosing 110 mg oral, twice daily
150 mg oral, twice daily
20 mg oral da
15 mg oral da
(if CrCl 30–49
Elimination 80% renal ~66% renal
Pro-drug Yes No
Half-life (h) 12–17 5–9 (9–13 h i
Tmax (h) 1 2–4
CrCl: creatinine clearance.respectively, p=0.31) and the 110mg dose of dabigatranwas associat-
ed with a 20% risk reduction (2.7% vs. 3.4% events/year, p = 0.003).
When the major bleedings were evaluated independently according
to their locations, the rate of intracranial haemorrhages was seen to be
signiﬁcantly lower in both of the dabigatran arms (110 mg BID and
150 mg BID) than it was in the warfarin arm (0.23%, 0.35% and
0.74% events/year respectively, p b 0.001 for both groups). On the
other hand, it was seen that the 150 mg dose of dabigatran increased
the risk for gastrointestinal bleeding when compared to warfarin
(1.51% and 1.02% respectively, p b 0.001), and the 110 mg dose of
dabigatran was similar to warfarin (1.12% and 1.02% respectively,
p = 0.43).13
Rivaroxaban
Rivaroxaban is a direct factor Xa inhibitor. Its half-life is 5–9 h
(9–13 h in the elderly) and 60–70% of the drug is excreted renally.11
The ROCKET-AF (Rivaroxaban Once daily oral direct factor Xa inhibition
compared with vitamin K antagonism for prevention of stroke and
Embolism Trial in Atrial Fibrillation) trial is a prospective, randomised,
double-blind trial comparing rivaroxaban and warfarin in patients
with non-valvular AF. Total of 14,264 patients with non-valvular
AF with mean CHADS2 scores of 3.48 were included in the trial.
Patients were randomised to receive 20 mg/day doses of rivaroxaban
(15 mg/day if the creatinine clearance is 30–49 mL/min) or warfarin
(target INR: 2–3). The primary endpointswere stroke and systemic em-
bolism. When the trial was completed, it was shown that rivaroxaban
was non-inferior to warfarin with respect to the primary endpoint
(2.1% vs. 2.4% respectively, for non-inferiority p b 0.001). There was
no difference between the rates of major and clinically signiﬁcant
non-major bleeding rates between rivaroxaban and warfarin groups
(14.9% vs. 14.5% events respectively, p = non-signiﬁcant). In addition,
the rate of intracranial haemorrhages was signiﬁcantly lower in the
rivaroxaban group (0.5% and 0.7% events/year, p = 0.02).14
Apixaban
Apixaban is an oral drug and is a direct competitive factor Xa inhib-
itor. It is absorbed rapidly, has a half-life of 10–14 h and 27% of the
drug is excreted renally.15 The AVERROES trial (Apixaban Versus
Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients
WhoHave Failed or Are Unsuitable for VitaminKAntagonist Treatment)
is a double-blind randomised trial including 5599 patients with AF for
whom vitamin K antagonist therapy is inappropriate. The patients
were randomised to receive apixaban (5 mg, twice a day) or aspirin
(80–325 mg). The mean follow-up was 1.1 years. The rate of stroke or
systemic embolism was 1.6% in the apixaban group and 3.7% in the as-
pirin group (HR 0.45, 95% CI 0.32–0.62, p b 0.001). It was recommended
to terminate the trial early because a signiﬁcant beneﬁt in favour of
apixaban was demonstrated. There was no signiﬁcant difference in
major bleeding rates between apixaban and aspirin groups. In addition,
it was shown that apixaban was tolerated better than aspirin as more
cases in the aspirin group discontinued their treatment.16Apixaban Edoxaban
a inhibition Direct factor Xa inhibition Direct factor Xa inhibition
ily
ily
mL/min)
5 mg oral, twice daily
2.5 mg oral, twice daily
(if creatinine N 133 mmol/L)
60 mg oral daily
30 mg oral daily
~27% renal 50% renal
No No
n the elderly) 10–14 9–11
3–4 1–4
Table 2
Comparison of data from major trials for the novel oral anticoagulants.12,14,15,20
RE-LY ROCKET-AF ARISTOTLE ENGAGE AF-TIMI 48
Treatment arms Dabigatran (110 mg or 150 mg,
twice a day) vs. warfarin
(target INR: 2–3)
Rivaroxaban 20 mg/day (15 mg/day
if the creatinine clearance is
30–49 mL/min) vs. warfarin (INR: 2–3)
Apixaban (5 mg, twice a day) vs.
warfarin (target INR: 2–3)
Edoxaban (30 mg/d or 60 mg/d)
vs. warfarin (target INR: 2–3)
Trial design Randomised, open-label Randomised, double-blind Randomised, double-blind Randomised, double-blind
Number of patients 18.113 14.264 18.201 21.105
Mean age 71.5 73 70 72
TTR of warfarin (%) 64 55 62 68
Mean CHADS2 score 2.1 3.48 2.1 2.8
Primary endpoint: stroke/
systemic embolism
(%/year)
1.53 in 110 mg dabigatran group,
1.11 in 150 mg dabigatran group
1.69 in warfarin group
(p b 0.001 for non-inferiority for
both dabigatran groups)
2.1 in rivaroxaban group and 2.4 in
warfarin group
(p b 0.001 for non-inferiority)
1.27 in apixaban group and 1.6
in warfarin group
(p b 0.001 for non-inferiority and
p = 0.01 for superiority)
1.61 in 30 mg edoxaban group,
1.18 in 60 mg edoxaban group
and 1.50 in warfarin group
(p = 0.005, p b 0.001 for
non-inferiority respectively)
INR: international normalised ratio; TTR: time-in-therapeutic range.
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Other Thromboembolic Events in Atrial Fibrillation) compared apixaban
to warfarin. This trial was a double-blind, randomised, controlled non-
inferiority trial and included 18,201 patients with non-valvular AF
with CHADS2 scores of 2.1 from 39 countries. The mean follow-up was
1.8 years. Patients were randomised to receive apixaban (5 mg, twice
a day) or warfarin. Patients who met two or more of the following
criteria were administered half doses of apixaban: being over 80 years
of age, weighing 60 kg and less or having serum creatinine levels higher
than 1.5 mg/dL. The primary composite endpoint, stroke or systemic
embolism occurred in 212 (1.27%) patients in the apixaban arm and
265 (1.6%) patients in the warfarin arm (p b 0.001 for non-inferiority,
p = 0.01 for superiority).
According to the results, apixaban was superior to warfarin in
preventing stroke and systemic embolisms in patients with non-
valvular AF. Apixaban was also superior to warfarin with respect to
all-cause mortality rates (3.52% vs. 3.94%, p = 0.047). Regarding the
safety endpoints, major bleeding occurred less in the apixaban arm
(2.13%) than the warfarin arm (3.09%) (p b 0.001). The rate of intracra-
nial haemorrhages was 0.33% event/year in the apixaban group and
0.80% event/year in the warfarin group (p b 0.001).15
Edoxaban
Edoxaban is a direct, speciﬁc and reversible inhibitor of factor Xa, de-
livered orally. Edoxaban has a half-life of approximately 9–11 h and its
absolute oral bioavailability is 62%. It quickly reaches peak plasma con-
centrations in 1.5 h and 50% of drug elimination is via the kidneys.17 The
Effective Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-
TIMI 48) is a randomised, double-blind, multicentre trial comparing
warfarin and edoxaban for thromboembolism and stroke prophylaxis
in non-valvular atrial ﬁbrillation. From 1393 hospitals in 46 countries,
21.105 subjects with a average CHADS₂ score of 2.8 were randomized
to edoxaban high dose (60 mg daily), edoxaban low dose (30 mg
daily), or warfarin titrated to an international normalised ratio of 2.0
to 3.0. The primary compound endpoint was systemic embolism and
stroke. Annual rate of the primary end point was 1.50% with warfarin
(time-in-therapeutic range (TTR), 68%), when compared to 1.18% with
60 mg edoxaban (p b 0.001 for non-inferiority) and 1.61% with 30 mg
edoxaban (p=0.005 for non-inferiority). Annual rate ofmajor bleeding
was 3.43% in warfarin, 2.75% and 1.61% for 60 mg and 30 mg edoxaban
treatment respectively (p b 0.001 for both doses). Both doses of
edoxaban were shown to be as efﬁcient as warfarin for systemic embo-
lism and stroke prophylaxis in non-valvular AF and were associated
with signiﬁcantly lower rates of bleeding and death from cardiovascular
causes. On the other hand gastrointestinal bleeding rates were signiﬁ-
cantly higher in edoxaban 60 mg group compared to warfarin therapy
(1.51% vs 1.23%; p = 0.03).18We can summarise the four randomised controlled novel oral anti-
coagulant trials as follows:
1- In patients with non-valvular AF, novel oral anticoagulants are at
least as effective aswarfarin for the prevention of stroke and systemic
embolism.12,14,15,18
2- When compared to warfarin, 150 mg doses of dabigatran reduced
the relative risk by 34% and apixaban reduced it by 21%. Both of
these drugs were superior to warfarin in preventing the primary
endpoint.12,15
3- The rates of intracranial haemorrhages and haemorrhagic stroke
were signiﬁcantly lower with novel oral anticoagulants. However,
only 150 mg doses of dabigatran were proven to be superior to
warfarin in preventing ischemic stroke (relative risk reduction
24%).12,14,15,18
4- Only apixaban is superior to warfarin with respect to mortality of all
causes (p = 0.047).15
5- With respect to other major bleedings except gastrointestinal
bleeding, apixaban, 110 mg doses of dabigatran and both
doses of edoxaban are safer than warfarin (superior). Rivaroxaban
and 150 mg doses of dabigatran are at least as safe as warfarin
(non-inferior).12,14,15,18
6- Rivaroxaban, 150 mg doses of dabigatran and 60 mg doses of
edoxaban increase the risk of gastrointestinal bleeding when com-
pared to warfarin. Apixaban, 110 mg doses of dabigatran and
30 mg doses of edoxaban are similar to warfarin (Table 2).12,14,15,18
Limitations to NOACs
The novel oral anticoagulant drugs have become popular in patients
with non-valvular AF for the prevention of stroke and ischaemic
embolisms because they do not require monitoring, they are easy to
use and they cause fewer drug and food interactions. However, the dif-
ferent designs and inclusion criteria of the trials comparing NOACs, and
the lack of trials comparing all three NOACs with each other raise con-
troversy. The four large phase III trials (RE-LY, ROCKET-AF, ARISTOTLE
and ENGAGE AF-TIMI 48) were all designed as non-inferiority trials.
The RE-LY trial was an open-labelled trial but the ROCKET-AF,
ARISTOTLE and ENGAGE AF-TIMI 48 trials were double-blind.12,14,15,18
In current guidelines, effective warfarin therapy is deﬁned as an “INR
level between 2.0 and 3.0 and the TTR as at least 70% of the entire treat-
ment duration”.1 The TTR in these trials differs signiﬁcantly, the TTR
is 55% in the ROCKET-AF trial, 62% in the ARISTOTLE trial, 64% in the
RE-LY trial and 68% in the ENGAGE AF-TIMI 48 trial. Due to suboptimal
time-in-therapeutic range the efﬁcacy of warfarin could have been cal-
culated lower than it should have been, thus, NOACsmay have been de-
termined as relatively non-inferior and/or superior to warfarin.19
Another important topic for discussion is the inclusion of patients
from different risk groups for stroke. The mean CHADS2 scores in the
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2.1, 2.8 and 3.5 respectively. This may be one of the reasons why
rivaroxaban was not superior to warfarin with respect to the primary
endpoints although apixaban and 150 mg doses of dabigatran were su-
perior. Another discussion topic is the association of dabigatran therapy
with ischaemic myocardial events. This discussion was raised because
the number ofmyocardial infarctions (MI)was higher in the dabigatran
arm of the RE-LY trial than the warfarin arm. Due to this, MI, unstable
angina, cardiac arrest and cardiac death rates on dabigatran treatment
were analysed and published. The annualMI rates in the arms receiving
110 mg or 150 mg of dabigatran or apixaban were 0.82%, 0.81% and
0.64% respectively and there was no statistically signiﬁcant difference.
There was no signiﬁcant difference between the rates of the primary
composite endpoints unstable angina, MI, cardiac arrest and cardiac
death either.20
Novel oral anticoagulants in light of guidelines
In the AF guideline and updates published by the European Society
of Cardiology (ESC) in 2010 and 2012 it is stated that AF patients must
undergo risk classiﬁcation for stroke and the anticoagulant treatment
requirements should be determined accordingly. For this purpose, in-
stead of the CHADS2 score it is recommended to use the CHA2DS2-
VASc score that allows better differentiation of the “real low risk”
cases.1 The ESC guideline does not recommend anticoagulant treatment
for non-valvular AF patients in the real low-risk groups — i.e. patients
under 65 years of age with no risk factors (with a CHA2DS2-VASc score
of 0). Oral anticoagulants are offered as the single treatment option for
cases with CHA2DS2-VASc scores ≥1. Female patients are given 1 point
for gender under any circumstance, however, they are not suitable can-
didates for anticoagulant therapy if they are under 65 years and have no
risk factors. In other words, anticoagulant treatment is indicated for all
patients with AF over the age of 65. If the patient has a rheumatoid
heart disease (especiallymitral stenosis), a history of prosthetic valvular
operations ormitral valve repair, and if the creatinine clearance is under
30mL/min the only suitable oral anticoagulant (OAC) is warfarin. In the
rest of the patients with non-valvular AF, warfarin and all three NOACs
are suitable for the same indications and have equivalent proof levels.21
The American College of Cardiology and the American Heart Associ-
ation (ACC/AHA) have updated the guidelines they published in 2014 to
recommendusing theCHA2DS2-VASc score for risk classiﬁcation instead
of the CHADS2 score in a similar fashion to the ESC guidelines.22 The
common aspects and differences between the guidelines important for
clinical practice issued by the ESC and ACC/AHA can be summarised as
follows:
⁎ The ESC guidelines recommend OAC treatment for patients with
CHA2DS2-VASc scores of 1, the ACC/AHA guidelines state that treat-
ment may not be necessary, OAC treatment can be administered or
treatment with aspirin may be considered.21,22
⁎ In patients with CHA2DS2-VASc scores of 0 both guidelines state that
treatment is not required.21,22
⁎ The ESC guidelines do not recommend using NOACs in patients who
have renal failure with CrCl (creatinine clearance) b30 mL/min, the
ACC/AHA guidelines state that NOACs should not be used in end-
stage chronic renal failure patients (CrCl b 15 mL/min) or in cases
in haemodialysis programs and that warfarin is the drug of choice
for these patients.21,22
⁎ The ESC guidelines recommend using a 110 mg dose of
dabigatran twice a day for patients with renal failure and CrCl =
30–49 mL/min. The ACC/AHA guidelines state that 150 mg or
75mg BID doses of dabigatran can be used in this patient group.21,22
⁎ The ACC/AHAguidelines state that 75mgdoses of dabigatran twice a
day or 15 mg/day doses of rivaroxaban can be used in renal failure
patients with CrCl = 15–30 mL/min. However, it is stated that this
recommendation is not based on data from prospective studies.22Monitoring novel oral anticoagulants
Unlikewarfarin, the novel oral anticoagulants do not require routine
monitoring. It may be necessary to assess the efﬁcacy of NOACs in some
speciﬁc clinical situations such as bleeding, newly developed or deteri-
orating renal failure, stroke or systemic embolism.23 However, there is
no speciﬁc coagulation test that can be used to determine the efﬁcacy
of theNOACdrugs in these clinical conditions. Themost useful approach
used for this purpose ismeasuring the thrombin or ecarin clotting times.
Especially during emergencies, the activated partial thromboplastin
time is another measure that can be used during dabigatran treatment.
However, it must not be forgotten that high blood levels of the drugs
may lead to erroneous activated partial thromboplastin time readings.24
The coagulation test used for rivaroxaban patients is the prothrombin
test.25 The factor Xa levels can also be used to monitor rivaroxaban,
apixaban and edoxaban.25,26
Bleeding management
There are a few novel antidotes used to antagonise drug effects in
bleedings induced by NOACs. Treatment with plasma is ineffective be-
cause the bleeding is not due to factor deﬁciency; thrombin and factor
Xa inhibitors are already present in the patient's blood. It is thought
that cryoprecipitate may be useful in dabigatran-induced bleedings
and that prothrombin concentrates may be useful in apixaban or
rivaroxaban-induced bleedings. The only emergency approach proven
to be useful in the treatment of dabigatran-induced bleeding is the use
of activated charcoal followed by haemodialysis to remove the drug
from the body.27 Currently, there is a few new speciﬁc antidote drugs
to treat major bleedings associated with new generation oral anticoag-
ulants. Thus, the most important point that needs to be considered by
the physician is the selection of the most suitable drug and dose
regimen.
Converting from anticoagulant treatment to NOACs and the
perioperative approach
The use of novel oral anticoagulants is increasing as they have ad-
vantages over warfarin. Their onset of effect is rapid, they do not cause
signiﬁcant food and drug interactions and they do not require monitor-
ing. If a patient on NOAC therapy is going to have surgery the most im-
portant question is when to stop the drug before the surgery. The
deﬁnitive issue is the functional capacity of the patient's kidneys. Ac-
cording to current consensus reports it is recommended to assess the
creatinine clearance at least seven days before the surgery before mak-
ing a decision. Important aspects to consider when deciding when to
stop NOAC therapy before surgery are given in Table 3.
When converting from warfarin to one of the novel oral anticoagu-
lants, the novel oral anticoagulant must be started when the INR is
below 2, in the opposite case double-treatment must be continued
until INR reaches efﬁcient levels. When converting from low molecular
weight heparin (LMWH) to new generation oral anticoagulants heparin
must be discontinued after delivering theﬁnal dose, and the newgener-
ation oral anticoagulant must be started 2 h before the time of the next
dose of heparin that was to have been administered. In the opposite
case, the ﬁrst dose of heparin must be delivered 12 or 24 h after the
last dose of the novel oral anticoagulant.27 When it is desired to convert
to NOACs from infusions of unfractionated heparin the ﬁrst NOAC dose
should be administered at the time of the discontinuation of the
infusion.
In the postoperative period it is recommended to restart the NOAC
therapy as soon as possible once haemostasis is maintained. Intrave-
nous heparin or LMWH bridge treatment is not required in the postop-
erative period as the effects of NOACs end rapidly and once restarted
they rapidly reach therapeutic efﬁcacy within 2 h.28
Table 3
Preoperative interruption of novel oral anticoagulants.45,46,47
Drug Renal function
Low bleeding risk surgery
(last dose)
High bleeding risk surgery
(last dose)
Dabigatran
(150 mg twice daily)
Normal or mild impairment
(CrCl ≥ 50 mL/min)
24 h before surgery 48–72 h before surgery
Moderate impairment
(CrCl 30–49 mL/min)
48–72 h before surgery 96 h before surgery
Rivaroxaban
(20 mg once daily)
Normal or mild impairment
(CrCl ≥ 50 mL/min)
24 h before surgery 48–72 h before surgery
Moderate impairment
(CrCl 30–49 mL/min)
48 h before surgery 72 h before surgery
Apixaban
(5 mg twice daily)
Normal or mild impairment
(CrCl ≥ 50 mL/min)
24 h before surgery 48–72 h before surgery
Moderate impairment
(CrCl 30–49 mL/min)
48 h before surgery 72 h before surgery
CrCl: creatinine clearance.
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The drug interactions of NOACs are another important issue. Al-
though NOACs cause less drug interactions than warfarin, the drug in-
teractions of NOACs must be known and a detailed pharmaceutical
history of the patient must be obtained before prescribing these drugs.
Dabigatran requires an acidicmedium for absorption because it con-
tains tartaric acid.While antacids andH2 receptor antagonists do not af-
fect the absorption of dabigatran; pantoprazole, a proton-pump
inhibitor prevents the formation of an acidic medium and reduces the
absorption of dabigatran.29
The inhibition and induction of P-glycoprotein (P-gp) play an impor-
tant role in themetabolism of dabigatran and also affect its blood levels.
In patients using drugs like amiodarone, verapamil, quinidine, ketoco-
nazole that inhibit P-gp, dabigatran must be avoided or used with cau-
tion at low doses. On the other hand, it must not be forgotten
that concomitant use of the P-gp inducer rifampicin may reduce the
therapeutic efﬁcacy of dabigatran. In patients using ketoconazole,
clarithromycin, ritonavir and other protease inhibitors that inhibit
CYP3A4, apixaban and rivaroxaban must be used with caution because
the blood levels and efﬁcacy of the drugs may increase.29New antidotes for novel oral anticoagulants
Life-threatening bleeding is the most important complication of
NOACs. Lack of antidotes for NOACs is another crucial point when ur-
gent intervention or surgery is needed.30 That brings the necessity of
a fast-affecting and speciﬁc antidote for reversal of anticoagulation.
Clinical trials in progress are evaluating the efﬁcacy and safety of
idarucizumab and andexanet alpha.31Dabigatran and idarucizumab
Idarucizumab (aDabi-Fab, BI 655075)which is a humanmonoclonal
antibody is the ﬁrst speciﬁc dabigatran antidote. Binding speciﬁcally to
dabigatran, idarucizumab antagonises its effects. Compared to thrombin
it has a 350-fold increased afﬁnity to dabigatran.32 ‘The Study of the
REVERSal Effects of Idarucizumab in Patients on Active Dabigatran
(RE-VERSE AD)’ is a phase 3 trial investigating the efﬁcacy and safety
of idarucizumab in patients with life-threatening bleeding and/or pa-
tients require urgent surgery or intervention.33 In this prospective co-
hort study, anticoagulation reversal capacity of 5 mg of idarucizumab
is evaluated by measuring diluted thrombin time (dTT) and ecarin
clotting time (ECT) before and 4 h after administration of idarucizumab.
According to the pre-analysis results of the study, in patients with
an increased coagulation proﬁle (elevated dTT in 68; elevated ECT in
81 patients) median maximum reversal rate was 100%.34Factor Xa inhibitors and andexanet alfa
Andexanet alfa (PRT064445, r-Antidote; Portola Pharmaceuticals) is
an enzymatically inactivemodiﬁed recombinant human factor Xa decoy
protein which has an increased afﬁnity to factor Xa inhibitors
(rivaroxaban, apixaban and edoxaban) and antagonises the anticoagu-
lant effects.35 Andexanet Alfa, a Novel Antidote to the Anticoagulation
Effects of FXA Inhibitors Apixaban (ANNEXA-A) and Rivaroxaban
(ANNEXA-R) trials are designed to evaluate the efﬁcacy and safety of
andexanet alfa, which is used to antagonise the anticoagulant effects
of apixaban and rivaroxaban in healthy volunteers. In this randomised,
placebo controlled, double-blind trial 101 participants between ages
50–75 years (48 patients in apixaban and 53 patients in rivaroxaban
arm) were randomised to either andexanet alfa or placebo. In
andexanet alfa arm, following the administration of the antidote, the ac-
tivity of anti-factor Xa decreased rapidly and signiﬁcantly within mi-
nutes (2–5 min) compared to placebo (andexanet alfa vs. placebo,
decreasing of anti-faactor Xa for apixaban [mean ± SD] 94 ± 2% vs.
21 ± 9%; p b 0.001, for rivaroxaban için 92 ± 11% vs 18 ± 15%;
p b 0.001).36
Real-world data of NOACs
Current guidelines recommendNOAC drugs for prevention of stroke
in non-valvular AF patients. Recommendations and level of evidences of
the guidelines are based on randomised trials of NOACs. Nevertheless,
as some patient groups which are common in routine daily practice
are not included in those trials, real-world data investigating the safety
and efﬁcacy of NOACs is needed. Designed for that purpose, XANTUS
trial is an international, large-scaled, prospective, observational study
collecting the real-world data of rivaroxaban which is used in stroke
prevention in non-valvular AF patients. A total of 6784 patients (mean
age: 71.5 years, 59% male) who were treated with rivaroxaban for
non-valvular AF were included in the study and were followed up for
one year independent of the risk of stroke. Mean CHADS2 score was
2.0. Mild to severe renal insufﬁciency (CrCl b 50 mL/min) was seen in
9.4% of patients. In safety results of the trial, fatal bleeding (0.2 events
per 100 p/y) in 0.2% of patients and major bleeding (n = 128,
2.1 events per 100 p/y) in 1.9% of patients occurred. Symptomatic
thromboembolism (stroke, transient ischaemic attack, systemic embo-
lism, MI) was seen in 1.6% of patients (n:108). In comparison with
ROCKET-AF trial, mean CHADS2 score (3.5 for ROCKET-AF and 2.0 for
XANTUS), all-cause mortality rates, major bleeding, stroke and MI
rates were lower in XANTUS trial.37
United States Department of Defence Post-marketing Safety Surveil-
lance (PMSS) trial is a retrospective, observational study designed to
identify the major bleeding incidence associated with rivaroxaban. A
total of 39.052 patients who were treated with rivaroxaban for total
hip/knee surgery or non-valvular AF were included in the study.
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100 person-years (n = 970). Most of the major bleedings were gastro-
intestinal bleedings (846 patients, 87.2%). Fatal bleeding incidence was
0.1% (n= 35). Intracranial haemorrhages were responsible for 74.3% of
fatal bleeding.38 Results of the study were consistent with ROCKET-AF
trial. The results of XANTUS and PMSS trials analysing the real-world
data conﬁrmed the results of ROCKET-AF trial.39
Effectiveness and Safety of Dabigatran and Warfarin in Real-world
US Patients With Non-Valvular Atrial Fibrillation: A Retrospective
Cohort Study is a retrospective, observational study, conducted between
2010 and 2012, including patients with non-valvular AF on vitamin K
antagonists or dabigatran therapy. A total of 64.935 patients were in-
cluded in the study of whom 32.5% were on dabigatran therapy. Com-
pared to warfarin, dabigatran was associated with lower risks of
ischaemic stroke or systemic embolism (composite adjusted HR: 0.86,
95% CI: 0.79 to 0.93), haemorrhagic stroke (HR: 0.51, 95% CI: 0.40 to
0.65) and MI (HR: 0.88, 95% CI: 0.77 to 0.99). Conversely dabigatran
was associated with increased risk of GI bleeding (HR: 1.11, 95% CI:
1.02 to 1.22).40 Supportively, Graham et al. conducted a study with
real-world data toﬁnd that 150mgdabigatranwas associatedwith less-
er death, ischaemic stroke, intracranial haemorrhage risks and therefore
increased GI bleeding risk.41 On the contrary, in a trial by Hernandez
et al. Dabigatran was associated with increased risks of bleeding (HR:
1.30, 95% CI: 1.20–1.41), major bleeding (HR: 1.58, 95% CI: 1.36–1.83)
andGI bleeding (HR: 1.85, 95% CI: 1.64–2.07). Intracranial haemorrhage
was signiﬁcantly lesser in dabigatran arm, similar to RE-LY trial. Investi-
gators emphasize that bleeding risk was higher especially in patients
with co-dominant comorbidities and that dabigatran should be used
with caution in those patients.42 In a recent report published by FDA
which was based on real-world data, dabigatran was associated with
lower risks of stroke, death and intracranial haemorrhage.43 In a trial
which was conducted between 2007 and 2010 and was evaluating
real-world data of non-valvular AF patients, NOACs were associated
with lower rates of stroke compared to warfarin. It was emphasised
that when excluding intracranial haemorrhages, apixaban was the
only NOAC decreasing major bleeding rates. Numbers needed to treat
(NNT) values for net clinical beneﬁt (stroke plus major bleeding except
intracranial haemorrhage) were 32 and 84 for apixaban and dabigatran
respectively.44Conclusions
The novel oral anticoagulant drugs for prevention of stroke in non-
valvular AF have been evolved and adding new options and advantages
for patients and physicians such as fewer frequency of drug and food
interactions, no need for monitoring, broad therapeutic index and
tolerated better by patients.
Large-scale phase III trials are completed for dabigatran,
rivaroxaban, apixaban, edoxaban and all these trials ended up with
non-inferiority of these new anticoagulant drugs compared with warfa-
rin for prevention of stroke for patients with non-valvular atrial ﬁbrilla-
tion. Additionally, compared with VKA, dabigatran 150 mg and
apixaban twice daily were superior and associated with signiﬁcant re-
ductions in the incidence of stroke. Intracranial haemorrhages and
haemorrhagic stroke occurred signiﬁcantly less with novel oral antico-
agulants. Especially in patients with poorly controlled INR values in
follow-up, the potential advantages of the NOACS are likely to be most
manifest.Conﬂict of interest
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